Evaluation of the Risk of Hyperoxia-induced Hypercapnia in Obese Cardiac Surgery Patients

May 5, 2018 updated by: François Lellouche, Laval University

Evaluation of the Risk of Hyperoxia-induced Hypercapnia in Obese Patients in a Cardiac Surgery Postoperative Setting

This study aims to evaluate the risk of hyperoxia-induced hypercapnia in post-op obese cardiac surgery patients. It will compare two oxygenation modes in terms of their effect on the arterial partial pressure of carbon dioxide (PaCO2) : manual titration of oxygen delivery for a peripheral oxygen saturation (SpO2) target of > or = 95 % versus automatic titration by a closed-loop system for a SpO2 target of 90%. 15 post-op obese cardiac surgery patients will be recruited and each will receive both interventions (cross-over design). The main outcome will be the PaCO2, which will be compared after each study period. The research hypothesis is that the usual SpO2 target of > or = 95 % is associated with a greater PaCO2 compared with a lesser SpO2 target of 90%.

Study Overview

Status

Completed

Intervention / Treatment

Detailed Description

This study aims to evaluate the risk of hyperoxia-induced hypercapnia in post-op obese cardiac surgery patients.

The investigators will compare two oxygenation modes in terms of their effect on PaCO2 : a SpO2 target of > or = 95 % achieved with manual titration (usual practice) and a more conservative SpO2 target of 90 % achieved with automatic titration by a closed-loop system (FreeO2).

The choice of a SpO2 target of 90 % is consistent with recent guidelines issued by the British Thoracic Society and the Thoracic Society of Australia and New Zealand, which both recommend a SpO2 target of 88-92 % for morbidly obese patients (BMI > 40 kg/m2).

FreeO2 is a closed-loop oxygen delivery system which adjusts the oxygen flow according to the patient's real-time SpO2 and a target programed by the physician. The system also records data on heart rate, respiratory rate and SpO2. Its safety and efficacy have been tested in healthy subjects as well as in patients suffering from COPD or acute respiratory distress in the emergency room, with promising results.

The research hypothesis is that the usual SpO2 target of > or = 95 % is associated with a greater PaCO2 compared with a lesser SpO2 target of 90%.

30 obese patients will be recruited* at the Institut universitaire de cardiologie et de pneumologie de Québec. A written consent from the patient will be obtained the day before the surgery. The protocol has been submitted to and approved by the establishment's ethics committee.

The study will compare the effect of two different oxygenation modes on the patients' PaCO2 immediately after extubation :

FreeO2 mode : oxygen delivered by nasal cannula or Venturi mask (if flow > 5L/min during > 5 minutes), automatically titrated for a SpO2 of 90 +/- 2 %

Usual mode : oxygen delivered by Venturi mask, manually titrated for a SpO2 superior or equal to 95 % (the local protocol is to deliver a post-extubation FiO2 which is 10 % superior to the pre-extubation FiO2)

Patients meeting all of the eligibility criteria will be randomized in the postoperative period. After extubation, they will receive oxygen for 30 minutes according to FreeO2 mode or the usual mode, depending on randomization. After 30 minutes, a first arterial blood gas will be obtained through their arterial cannula. Next, they will be oxygenated according to the second oxygenation mode for another 30 minutes, after which a second arterial blood gas will be obtained. Each patient will thus act as his own control (cross-over design).

When patients will be oxygenated according to the usual mode, FreeO2 will be in recording mode, but will not be delivering any oxygen.

The study will last 1h for each patient, and will have to begin within 30 minutes after extubation. A member of the research team will be at the patient's bedside for the whole data collecting period.

Complete data collection should be achieved within 12 months.

Demographic data (age, sex, weight, height and BMI) will be collected upon study entering as well as pre-operative room air PCO2 on capillary blood gas, type of surgery (number of bypass grafts, extracorporal circulation time), opiates dosage per-op and post-op, and pre-op left ventricular ejection fraction and renal function. FreeO2 will be recording respiratory rate, heart rate and SpO2 for the whole study duration. The respiratory rate will also be recorded manually and on the monitor. When patients will be receiving oxygen from FreeO2, the system will record the delivered flow ; with the usual mode, the staff will record the delivered FiO2. At the end of each intervention, hemodynamic measures will be taken : systolic, diastolic and median arterial blood pressure, systolic, diastolic and median pulmonary artery pressure and amine level.

*Initially, 15 patients were supposed to be included. After inclusion of those 15 patients, statistical analyses showed a lack of statistical power and a possibly significant difference in PaCO2, but only in half the patients. We thus submitted a protocol amendment to our institution's ethics committee to enlarge the sample size to 30 patients, which was accepted on July 13th, 2017.

Study Type

Interventional

Enrollment (Actual)

30

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Québec, Canada, G1V4G5
        • Institut Universitaire De Cardiologie Et De Pneumologie De Québec

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • BMI > 30 kg/m2
  • SpO2 > or = 95 % before extubation
  • Procedure : coronary artery bypass

Exclusion Criteria:

  • Comorbidities : chronic obstructive pulmonary disease, cystic fibrosis, restrictive syndrome not associated with obesity (pulmonary fibrosis, neuromuscular junction disease, etc.)
  • Obstructive sleep apnea requiring a positive-pressure mask in the posteoperative period
  • FreeO2 device unavailable
  • Inclusion in another study that does not permit dual inclusion

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Supportive Care
  • Allocation: Randomized
  • Interventional Model: Crossover Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Active Comparator: Group A
15 patients who will receive usual care for 30 minutes and then switch to FreeO2 for another 30 minutes
Oxygen delivery automatically titrated by a closed-loop system that adjusts the oxygen flow based on the patient's real-time SpO2 and a programed SpO2 target of 90 %
Oxygen delivery manually titrated by the nursing staff for a SpO2 target of > or = 95 %
Active Comparator: Group B
15 patients who will be oxygenated by FreeO2 for 30 minutes and then switch to usual care for another 30 minutes
Oxygen delivery automatically titrated by a closed-loop system that adjusts the oxygen flow based on the patient's real-time SpO2 and a programed SpO2 target of 90 %
Oxygen delivery manually titrated by the nursing staff for a SpO2 target of > or = 95 %

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Difference in PaCO2
Time Frame: At 30 minutes (first intervention) and at 1h (second intervention)
Difference in end-of-period PaCO2 on arterial blood gas
At 30 minutes (first intervention) and at 1h (second intervention)

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Difference in pH
Time Frame: At 30 minutes (first intervention) and at 1h (second intervention)
Difference in end-of-period pH on arterial blood gas
At 30 minutes (first intervention) and at 1h (second intervention)
Difference in PaO2
Time Frame: At 30 minutes (first intervention) and at 1h (second intervention)
Difference in end-of-period PaO2 on arterial blood gas
At 30 minutes (first intervention) and at 1h (second intervention)
Difference in percentage of time spent in hypoxemia (SpO2 < 88%)
Time Frame: In the first 30 minutes (first intervention) and between 30 min and 1h (second intervention)
Difference in percentage of time spent in hypoxemia (SpO2 < 88%) between periods
In the first 30 minutes (first intervention) and between 30 min and 1h (second intervention)
Difference in percentage of time spent in severe hypoxemia (SpO2 < 85 %)
Time Frame: In the first 30 minutes (first intervention) and between 30 min and 1h (second intervention)
Difference in percentage of time spent in severe hypoxemia (SpO2 < 85 %) between periods
In the first 30 minutes (first intervention) and between 30 min and 1h (second intervention)
Difference in percentage of time spent in hyperoxemia (SpO2 > 96 %)
Time Frame: In the first 30 minutes (first intervention) and between 30 min and 1h (second intervention)
Difference in percentage of time spent in hyperoxemia (SpO2 > 96 %) between periods
In the first 30 minutes (first intervention) and between 30 min and 1h (second intervention)
Difference in respiratory rate (manual and monitor)
Time Frame: At 0, 10, 20, 30, 40, 50 and 60 minutes
Difference in respiratory rate (manual, monitor, FreeO2) between periods for each measuring technique (manual and monitor)
At 0, 10, 20, 30, 40, 50 and 60 minutes
Difference in mean heart rate
Time Frame: In the first 30 minutes and between 30 and 60 minutes
Difference in mean heart rate, recorded continuously by FreeO2, between periods
In the first 30 minutes and between 30 and 60 minutes
Difference in arterial blood pressure
Time Frame: At 0, 10, 20, 30, 40, 50 and 60 minutes
Difference in arterial blood pressure (systolic, diastolic and mean) between periods
At 0, 10, 20, 30, 40, 50 and 60 minutes
Difference in pulmonary artery pressure
Time Frame: At 0, 10, 20, 30, 40, 50 and 60 minutes
Difference in pulmonary artery pressure (systolic, diastolic and mean) between periods
At 0, 10, 20, 30, 40, 50 and 60 minutes
Difference in vasopressor dosage
Time Frame: At 0, 10, 20, 30, 40, 50 and 60 minutes
Difference in vasopressor dosagel at different times between periods
At 0, 10, 20, 30, 40, 50 and 60 minutes
Difference in body temperature
Time Frame: At 0, 10, 20, 30, 40, 50 and 60 minutes
Difference in body temperature at different times between periods
At 0, 10, 20, 30, 40, 50 and 60 minutes

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: François Lellouche, MD, PhD, Laval University

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

September 1, 2016

Primary Completion (Actual)

January 8, 2018

Study Completion (Actual)

January 8, 2018

Study Registration Dates

First Submitted

September 25, 2016

First Submitted That Met QC Criteria

September 26, 2016

First Posted (Estimate)

September 28, 2016

Study Record Updates

Last Update Posted (Actual)

May 11, 2018

Last Update Submitted That Met QC Criteria

May 5, 2018

Last Verified

May 1, 2018

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

YES

IPD Plan Description

The investigators would like to publish our results in scientific magazine and/or present them in a Conference.

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Obesity

Clinical Trials on FreeO2

3
Subscribe